Trust the gut: Outcomes of gut microbiota transplant in metabolic and cognitive disorders.

Neurosci Biobehav Rev

Institute of Clinical Physiology (IFC), the National Research Council (CNR), via Moruzzi 1, 56124 Pisa, Italy. Electronic address:

Published: June 2023

Type 2 diabetes mellitus (T2DM) is a main public health concern, with increasing prevalence and growingly premature onset in children, in spite of emerging and successful therapeutic options. T2DM promotes brain aging, and younger age at onset is associated with a higher risk of subsequent dementia. Preventive strategies should address predisposing conditions, like obesity and metabolic syndrome, and be started from very early and even prenatal life. Gut microbiota is an emerging target in obesity, diabetes and neurocognitive diseases, which could be safely modulated since pregnancy and infancy. Many correlative studies have supported its involvement in disease pathophysiology. Faecal material transplantation (FMT) studies have been conducted in clinical and preclinical settings to deliver cause-effect proof and mechanistic insights. This review provides a comprehensive overview of studies in which FMT was used to cure or cause obesity, metabolic syndrome, T2DM, cognitive decline and Alzheimer's disease, including the evidence available in early life. Findings were analysed to dissect consolidated from controversial results, highlighting gaps and possible future directions.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neubiorev.2023.105143DOI Listing

Publication Analysis

Top Keywords

gut microbiota
8
obesity metabolic
8
metabolic syndrome
8
trust gut
4
gut outcomes
4
outcomes gut
4
microbiota transplant
4
transplant metabolic
4
metabolic cognitive
4
cognitive disorders
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!